CHICAGO/NEW YORK (Reuters) – The first patient to be diagnosed with Ebola in a U.S. hospital was evaluated initially and turned away, a critical missed opportunity that could result in others being exposed to the deadly virus, infectious disease experts said.
On the patient’s first visit to Texas Health Presbyterian Hospital in Dallas last Friday, he walked into the hospital presenting “non-specific symptoms” and was sent home with a prescription for antibiotics, Dr. Edward Goodman, an infectious disease specialist at the hospital, told a news conference on Tuesday.
Your next flu shot might come from a tobacco plant: https://t.co/YSFFgQqbWs. Will it be smokable?
NEW YORK (Reuters) – Two tiny companies are preparing to challenge some of the world’s largest drug makers in the battle for dominance in the $3 billion global market for influenza vaccines, armed with little more than tiny tobacco plants.
The use of plants to produce life-saving pharmaceuticals captured global attention when it was revealed that the Ebola drug ZMapp is produced in the leaves of tobacco plants.
(Reuters) – A man who flew from Liberia to Texas has become the first patient infected with the deadly Ebola virus to be diagnosed in the United States, health officials said on Tuesday, a sign the outbreak ravaging West Africa may spread globally.
The patient sought treatment six days after arriving in Texas on Sept. 20, Dr. Thomas Frieden, director of the U.S. Centers for Disease Control and Prevention (CDC), told reporters. He was admitted two days later to an isolation room at Texas Health Presbyterian Hospital in Dallas.
Sept 30 (Reuters) – U.S. health officials said on Tuesday
the first patient infected with the deadly Ebola virus had been
diagnosed in the country, in a new sign of how the outbreak
ravaging West Africa can spread globally.
The patient had recently traveled to West Africa and
developed symptoms several days after returning to Texas, state
officials said. The patient was admitted to an isolation room at
Texas Health Presbyterian Hospital in Dallas.
NEW YORK (Reuters) – U.S. doctors and teaching hospitals received $3.5 billion from pharmaceutical companies and medical device makers in the last five months of 2013, according to the most extensive data trove on such payments ever made public.
The payments, disclosed by the Centers for Medicare and Medicaid Services (CMS) on Tuesday, include consulting and speaking fees, travel, meals, entertainment and research grants. The names of the recipients of about 40 percent of the payments reported by companies were withheld because CMS had concerns about data inconsistencies.